Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea

Authors: Eun-Jung Kim, Minsu Ock, Kyu-pyo Kim, Nuri Hyun Jung, Hyeon-Jeong Lee, Seon-Ha Kim, Min-Woo Jo

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Utility weight, a measure of health-related quality of life, is used in disease burden measurements and economic evaluations. In this study, we used the visual analogue scale (VAS) and standard gamble (SG) method to determine the utility weights of lung cancer health states in South Korea from a societal perspective.

Methods

Six hypothetical health states for lung cancer or a related health state reflective of disease severity were developed: 1) Stage I, 2) Stage II, 3) Stage IIIa, 4) Stage IIIB, 5) Stage IV, and 6) Pulmonary nodule. The description of each health state description was divided into four parts: diagnosis, symptoms, treatment, and progression and prognosis. A total of 515 representative adult Korean participants used a VAS and SG to evaluate these six health states via face-to-face computer-assisted interviews. The means, standard deviations, and median utility weights of the six health states were estimated by valuation method.

Results

The two valuation methods of the scenarios yielded the same mean utility rankings. Pulmonary nodule received the highest rank (VAS, 0.66 and SG, 0.83), whereas Stage 4 was assigned the lowest rank (VAS, 0.09 and SG, 0.31). For all health states, the mean utility weights calculated using the SG were greater than those calculated using the VAS. The differences between the utility weights obtained using the two valuation methods ranged from 0.14 (Stage I) to 0.22 (Stage IV). The two approaches tended to yield larger differences for more severe stages.

Conclusions

This study determined utilities for squamous cell lung cancer that will be useful for estimating the burden of lung cancer and for conducting economic evaluations of lung cancer interventions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yoon J, Oh IH, Seo H, Kim EJ, Gong YH, Ock M, et al. Disability-adjusted life years for 313 diseases and injuries: the 2012 Korean burden of disease study. J Korean Med Sci. 2016;31(2):S146–57.CrossRef Yoon J, Oh IH, Seo H, Kim EJ, Gong YH, Ock M, et al. Disability-adjusted life years for 313 diseases and injuries: the 2012 Korean burden of disease study. J Korean Med Sci. 2016;31(2):S146–57.CrossRef
2.
go back to reference Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from eastern cooperative oncology group study 5592. J Clin Oncol. 2003;21(8):1536–43.CrossRef Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from eastern cooperative oncology group study 5592. J Clin Oncol. 2003;21(8):1536–43.CrossRef
3.
go back to reference Kim EJ, Yoon SJ, Jo MW, Kim HJ. Measuring the burden of chronic diseases in Korea in 2007. Public Health. 2013;127(9):806–13.CrossRef Kim EJ, Yoon SJ, Jo MW, Kim HJ. Measuring the burden of chronic diseases in Korea in 2007. Public Health. 2013;127(9):806–13.CrossRef
4.
go back to reference Ock M, Han JW, Lee JY, Kim SH, Jo MW. Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040. Value Health. 2015;18(1):61–6.CrossRef Ock M, Han JW, Lee JY, Kim SH, Jo MW. Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040. Value Health. 2015;18(1):61–6.CrossRef
5.
go back to reference Han KT, Kim SJ, Lee SY, Park EC. Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals. Asian Pac J Cancer Prev. 2014;15(19):8503–8.CrossRef Han KT, Kim SJ, Lee SY, Park EC. Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals. Asian Pac J Cancer Prev. 2014;15(19):8503–8.CrossRef
6.
go back to reference Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics. 2009;27(9):767 7.CrossRef Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics. 2009;27(9):767 7.CrossRef
7.
go back to reference Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non–small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–203.CrossRef Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non–small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–203.CrossRef
8.
go back to reference Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with health utilities index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006;4:25.CrossRef Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with health utilities index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006;4:25.CrossRef
9.
go back to reference Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
10.
go back to reference Furlong W, Feeny D, Torrance GW, Barr R, Horsman J. Guide to design and development of health-state utility instrumentation, Working Paper No. 90-9. McMaster University, Centre for Health Economics and Policy Analysis; 1990. Furlong W, Feeny D, Torrance GW, Barr R, Horsman J. Guide to design and development of health-state utility instrumentation, Working Paper No. 90-9. McMaster University, Centre for Health Economics and Policy Analysis; 1990.
11.
go back to reference Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Mak. 2001;21(4):329–34.CrossRef Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Mak. 2001;21(4):329–34.CrossRef
12.
go back to reference Ock M, Park JY, Son WS, Lee HJ, Kim SH, Jo MW. Estimation of utility weights for human papilloma virus-related health states according to disease severity. Health Qual Life Outcomes. 2016;14(1):163.CrossRef Ock M, Park JY, Son WS, Lee HJ, Kim SH, Jo MW. Estimation of utility weights for human papilloma virus-related health states according to disease severity. Health Qual Life Outcomes. 2016;14(1):163.CrossRef
13.
go back to reference Kim SH, Jo MW, Ock M, Lee HJ, Lee JW. Estimation of health state utilities in breast cancer. Patient Prefer Adherence. 2017;11:531–6.CrossRef Kim SH, Jo MW, Ock M, Lee HJ, Lee JW. Estimation of health state utilities in breast cancer. Patient Prefer Adherence. 2017;11:531–6.CrossRef
14.
go back to reference Lee JY, Ock M, Jo MW, Son WS, Lee HJ, Kim SH, et al. Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea. Sci Rep. 2017;7(1):5571.CrossRef Lee JY, Ock M, Jo MW, Son WS, Lee HJ, Kim SH, et al. Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea. Sci Rep. 2017;7(1):5571.CrossRef
15.
go back to reference Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23(5):1104–10.CrossRef Blinman P, King M, Norman R, Viney R, Stockler MR. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23(5):1104–10.CrossRef
16.
go back to reference Hadorn DC. The role of public values in setting health care priorities. Soc Sci Med. 1991;32(7):773–81.CrossRef Hadorn DC. The role of public values in setting health care priorities. Soc Sci Med. 1991;32(7):773–81.CrossRef
17.
go back to reference Froberg DG, Kane RL. Methodology for measuring health-state preferences III : population and context effects. J Clin Epidemiol. 1989;42(6):585–92 25.CrossRef Froberg DG, Kane RL. Methodology for measuring health-state preferences III : population and context effects. J Clin Epidemiol. 1989;42(6):585–92 25.CrossRef
18.
go back to reference Froberg DG, Kane RL. Methodology for measuring health-state preferences V : Progress and research agenda. J Clin Epidemiol. 1989;42(7):675–85 26.CrossRef Froberg DG, Kane RL. Methodology for measuring health-state preferences V : Progress and research agenda. J Clin Epidemiol. 1989;42(7):675–85 26.CrossRef
19.
go back to reference Ubel PA, Richardson J, Menzel P. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. Health Econ. 2000;9:127–36.CrossRef Ubel PA, Richardson J, Menzel P. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. Health Econ. 2000;9:127–36.CrossRef
20.
go back to reference Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.CrossRef Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.CrossRef
21.
go back to reference Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res. 1994;29(2):207–24.PubMedPubMedCentral Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res. 1994;29(2):207–24.PubMedPubMedCentral
22.
go back to reference Dolan P, Sutton M. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997;44(10):1519–30.CrossRef Dolan P, Sutton M. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997;44(10):1519–30.CrossRef
23.
go back to reference Salomon JA, Murray CJ. A multi-method approach to measuring health-state valuations. Health Econ. 2004;13(3):281–90.CrossRef Salomon JA, Murray CJ. A multi-method approach to measuring health-state valuations. Health Econ. 2004;13(3):281–90.CrossRef
24.
go back to reference Parducci A, Wedell DH. The category effect with rating scales: number of categories, number of stimuli, and method of presentation. J Exp Psychol Hum Percept Perform. 1986;12(4):496–516.CrossRef Parducci A, Wedell DH. The category effect with rating scales: number of categories, number of stimuli, and method of presentation. J Exp Psychol Hum Percept Perform. 1986;12(4):496–516.CrossRef
25.
go back to reference Dolan P, Olsen JA, Menzel P, Richardson J. An inquiry into the different perspectives that can be used when eliciting preferences in health. Health Econ. 2003;12(7):545–51.CrossRef Dolan P, Olsen JA, Menzel P, Richardson J. An inquiry into the different perspectives that can be used when eliciting preferences in health. Health Econ. 2003;12(7):545–51.CrossRef
26.
go back to reference Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62(3):374–80.CrossRef Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62(3):374–80.CrossRef
27.
go back to reference Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Mak. 2010;30(6):685–93.CrossRef Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Mak. 2010;30(6):685–93.CrossRef
28.
go back to reference Swinburn P, Shingler S, Liu Y, Huang H, Acaster S. Health state utilities for relapsed/refractory Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL). Amsterdam: Poster presentation at: 17th congress of the European Hematology Association; 2012. p. 14–7. Swinburn P, Shingler S, Liu Y, Huang H, Acaster S. Health state utilities for relapsed/refractory Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL). Amsterdam: Poster presentation at: 17th congress of the European Hematology Association; 2012. p. 14–7.
29.
go back to reference Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–90.CrossRef Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–90.CrossRef
Metadata
Title
Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea
Authors
Eun-Jung Kim
Minsu Ock
Kyu-pyo Kim
Nuri Hyun Jung
Hyeon-Jeong Lee
Seon-Ha Kim
Min-Woo Jo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4960-y

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine